



Make your **mark.**

Discover reagents that make
your research stand out.

DISCOVER HOW



**IL-10 prevents naturally occurring fetal loss
in the CBA x DBA/2 mating combination, and
local defect in IL-10 production in this
abortion-prone combination is corrected by
in vivo injection of IFN- τ**

This information is current as
of August 9, 2022.

G. Chaouat, A. A. Meliani, J. Martal, R. Raghupathy, J.
Elliot, T. Mosmann and T. G. Wegmann

J Immunol 2005; 175:3447; ;
doi: 10.4049/jimmunol.175.5.3447-d
<http://www.jimmunol.org/content/175/5/3447.4>

Why *The JI*? Submit online.

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Fast Publication!** 4 weeks from acceptance to publication

**average*

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>




CORRECTIONS

Lum J. J., G. Bren, R. McClure, and A. D. Badley. 2005. Elimination of senescent neutrophils by TNF-related apoptosis inducing ligand. *J. Immunol.* 175: 1232–1238.

The word “apoptosis” was misspelled in the title, in the fourth sentence of the **Abstract**, in the first sentence of the third paragraph of the **Introduction**, and in the abbreviations list in **Footnotes**. The error has been corrected in the online version, which now differs from the print version as originally published.

Mattioli B., E. Straface, M. G. Quaranta, L. Giordani, and M. Viora. 2005. Leptin promotes differentiation and survival of human dendritic cells and licenses them for Th1 priming. *J. Immunol.* 174: 6820–6828.

In **Results**, in Fig. 7, the arrows indicating IL-4 and IFN- γ are inverted. The corrected figure is shown below.



Li, Z., W. K. Lim, S. P. Mahesh, B. Liu, and R. B. Nussenblatt. 2005. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56^{bright} regulatory NK cells in patients with active uveitis. *J. Immunol.* 174: 5187–5191.

In **Results and Discussion**, after the first sentence in the last paragraph, the authors wish to add the sentences shown below. In **References**, the authors also wish to add the citation shown below.

Recently, Bielekova et al. described their findings concerning the induction of CD56^{bright} NK cells by anti-IL2R therapy in multiple sclerosis patients (31). This is consistent with our observations in uveitis patients.

31. Bielekova, B., S. Reichert-Scrivner, M. Cerna, H. McFarland, and R. Martin. 2004. CD56^{bright} NK cells mediate immunomodulatory effects of IL-2R-targeted therapy in multiple sclerosis. *J. Neuroimmunology* 154: 211 (Abstr. 699).

Stuart L. M., K. Takahashi, L. Shi, J. Savill, and R. A. B. Ezekowitz. 2005. Mannose-binding lectin-deficient mice display defective apoptotic cell clearance but no autoimmune phenotype. *J. Immunol.* 174: 3220–3226.

In **Disclosures**, a potential financial conflict of interest was inadvertently omitted. The disclosure shown below should have been declared.

R. A. B. Ezekowitz is cofounder and serves on the Board of Directors of NatImmune, a privately held biotechnology company.

Mc Allister F., C. Steele, M. Zheng, E. Young, J. E. Shellito, L. Marrero, and J. K. Kolls. 2004. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. *J. Immunol.* 172: 1132–1138.

The first author's name is listed incorrectly. The correct name is Florencia McAllister.

Chaouat G., A. A. Meliani, J. Martal, R. Raghupathy, J. Elliot, T. Mosmann, and T. G. Wegmann. 1995. IL-10 prevents naturally occurring fetal loss in the CBA x DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN- τ . *J. Immunol.* 154: 4261–4268.

The fifth author's name is listed incorrectly. The correct name is John F. Elliott.